Boston Family Office LLC Sells 858 Shares of Stryker Co. (NYSE:SYK)

Boston Family Office LLC cut its holdings in Stryker Co. (NYSE:SYK) by 1.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,401 shares of the medical technology company’s stock after selling 858 shares during the quarter. Stryker makes up about 1.5% of Boston Family Office LLC’s investment portfolio, making the stock its 21st largest position. Boston Family Office LLC’s holdings in Stryker were worth $22,467,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in Stryker by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company’s stock valued at $2,539,033,000 after acquiring an additional 168,436 shares in the last quarter. Tradewinds LLC. purchased a new stake in shares of Stryker during the 4th quarter valued at $241,000. National Bank of Canada FI boosted its position in shares of Stryker by 69.6% in the 4th quarter. National Bank of Canada FI now owns 431,259 shares of the medical technology company’s stock worth $155,277,000 after purchasing an additional 177,033 shares in the last quarter. HighPoint Advisor Group LLC grew its stake in Stryker by 28.8% during the 4th quarter. HighPoint Advisor Group LLC now owns 4,356 shares of the medical technology company’s stock worth $1,701,000 after buying an additional 975 shares during the last quarter. Finally, Rodgers Brothers Inc. grew its stake in Stryker by 14.1% during the 4th quarter. Rodgers Brothers Inc. now owns 1,217 shares of the medical technology company’s stock worth $438,000 after buying an additional 150 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on SYK. Argus set a $450.00 price target on Stryker in a research note on Monday, February 3rd. Stifel Nicolaus increased their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Canaccord Genuity Group lifted their target price on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Wells Fargo & Company upped their price target on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Finally, The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research note on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $421.90.

Stryker Stock Performance

Shares of SYK stock opened at $372.73 on Tuesday. The company has a market capitalization of $142.27 billion, a P/E ratio of 48.03, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The business’s 50 day moving average is $383.86 and its two-hundred day moving average is $374.41. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the business posted $3.46 EPS. Analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. Stryker’s dividend payout ratio is currently 43.30%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.